Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (20CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

Authors :: Inwards, David J.
Fishkin, Paul A.S.
Hillman, David W.
Brown, David W.
Ansell, Stephen M.
Kurtin, Paul J.
Fonseca, Rafael
Morton, Roscoe F.
Veeder, Michael H.
Witzig, Thomas E.
Source :: Cancer. July 1, 2008, Vol. 113 Issue 1, 108
Publication Year :: 2008

Subjects :: Non-Hodgkin's lymphomas -- Drug therapy
Non-Hodgkin's lymphomas -- Research
Cladribine -- Dosage and administration
Cladribine -- Research
Drug therapy -- Patient outcomes
Health

Tools